Pfizer says it remains committed to getting 1.5 million doses of its vaccine into New Zealand this year.
The EU has laid out new export rules for pharmaceutical companies producing Covid-19 vaccines for third party countries.
In a statement, drug company said: “Pfizer committed to delivering on its agreement with the New Zealand government to supply 1.5 million doses of its vaccine for Covid-19 over the course of 2021.
READ MORE:* New Zealand ranked best at responding to Covid-19 pandemic, according to Lowy Institute* Covid-19: At the back of the coronavirus vaccine queue* Government rejects claim overseas production issues threaten access to vaccines * Covid-19: EU threatens drug companies with legal action if it doesn’t get its vaccines* Covid-19: PM says government approval for Pfizer vaccine possible next week* Covid-19: Pfizer, BioNTech plan nearly a billion more vaccine doses than expected* Covid-19 vaccines may have arrived quickly, but experts say that’s not a reason to fear them
“At this time, we are on track to deliver the first doses in February 2021. However, we look forward to receiving further details on the EU proposal and assessing its impact on patients.
“We understand the EU proposed notification process is aimed at increasing transparency and does not intend to restrict global supply to patients.
A vial of the Pfizer Covid-19 vaccine for COVID-19 is shown in the US at a one-day vaccination clinic set up in an Amazon.com facility.
“It is critical that governments do not impose export restrictions or other trade barriers that risk creating uncertainty and disrupting supply of vaccine to patients around the world.
“Pfizer will continue to work closely with the government to support their vaccine implementation plans.”
College of GPs medical director and former Pharmac deputy medical director Bryan Betty said the EU export restrictions were concerning and it was time for New Zealand to also start the conversation around manufacturing capability here.
He said it was important to get the vaccine in time.
“There’s three major issues here: there is a huge global demand and this nationalistic type approach that Europe may be taking could disrupt supply.
“The second thing we do see manufacturing problems with medications all the time.
“And the third issue is we’re at the end of a long global supply chain and as we saw last year with the flu vaccination, there was recurrent disruption to the supply of vaccine into the country.”
He said the government’s contracts with the vaccine companies should be watertight, and there might even be financial penalties, but the global competition for the vaccine was something to watch for.
It would be ideal to have all the country vaccinated by the end of the year, but there could be setbacks.
“We need to be realistic about that possibility. It may be out of New Zealand’s control.”